Publications
Scientific articles published by the researchers of Barcelonaβeta Brain Research Center (BBRC), related to Alzheimer's disease, neuroimaging, memory and neurodegenerative diseases, among other fields.
-
Argiris G, Akinci M, Peña-Gómez C, Palpatzis E, Garcia-Prat M, Shekari M, Blennow K, Zetterberg H, Kollmorgen G, Quijano-Rubio C, Ashton NJ, Karikari TK, Brinkmalm-Westman A, Lantero-Rodriguez J, Fauria K, Sánchez-Benavides G, Grau-Rivera O, Suárez-Calvet M, Arenaza-Urquijo EM.
Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease
Alzheimer's Research & TherapyAbstractBackground: Cerebrospinal fluid (CSF) biomarkers of synaptic dysfunction, neuroinflammation, and glial response, complementing Alzheimer's disease (AD) core biomarkers, have improved the...
-
Canals-Gispert L, Cañas-Martínez A, Huesa G, Suárez-Calvet Alomà M, Milà-Alomà M, Arenaza-Urquijo E, Cirillo D, Dimech AS, Iulita MF, Martinkova JN, Tartaglia MC, Quevenco FC, Chadha AS, Sánchez-Benavides G, Minguillón C, Ferretti MT, Fauria K, Brugulat-Serrat A
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer's prevention research cohort
Alzheimer's Research & TherapyAbstractBackground: Although there is growing evidence of the association between gender and early diagnosis of preclinical Alzheimer's disease, little attention has been given to the enrolment ratio of men...
-
Pilotto A, Quaresima V, Trasciatti C, Tolassi C, Bertoli D, Mordenti C, Galli A, Rizzardi A, Caratozzolo S, Zancanaro A, Contador J, Hansson O, Palmqvist S, De Santis G, Zetterberg H, Blennow K, Brugnoni D, Suárez-Calvet M, Ashton NJ, Padovani A.
Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison
BrainAbstractPlasma phosphorylated-tau217 (p-tau217) has been shown to be one of the most accurate diagnostic markers for Alzheimer's disease. No studies have compared the clinical performance of p-tau217 as...
-
Cacciaglia R, Shekari M, Salvadó G, Milà-Alomà M, Falcon C, Sánchez-Benavides G, Minguillón C, Fauria K, Grau-Rivera O, Molinuevo JL, Blennow K, Zetterberg H, Quevenco FC, Suárez-Calvet M, Gispert JD.
The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease.
Brain Commun.AbstractCSF concentrations of β-amyloid 42 (Aβ42) and phosphorylated tau (p-tau) are well-established biomarkers of Alzheimer's disease and have been studied in relation to several neuropathological features...
-
Buongiorno M, Sánchez-Benavides G, Marzal-Espí C, Giraldo DM, Krupinski J, Cullell N, Grau-Rivera O, Suárez-Calvet M, Gispert JD, de la Sierra A
Alzheimer's Disease Neuroimaging Initiative. Blood-brain barrier permeable β-blockers association with Alzheimer's disease cerebrospinal fluid biomarkers levels in non-demented individuals
Journal of Alzheimer's DiseaseAbstractβ-blockers that easily cross the blood-brain barrier (BBB) seem to diminish the risk of Alzheimer's disease (AD), hypothetically facilitating waste clearance. However, their effect on AD...
-
Zeng H, Schagen SB, Hendriks LEL, Sánchez-Benavides G, Jaspers JPM, Manero RM, Lievens Y, Murcia-Mejía M, Kuenen M, Rico-Oses M, Albers EAC, Samper P, Houben R, de Ruiter MB, Dieleman EMT, López-Guerra JL, De Jaeger K, Couñago F, Lambrecht M, Calvo-Crespo P, Belderbos JSA, De Ruysscher DKM, Rodríguez de Dios N.
Impact of HA-PCI on self-reported cognitive functioning and brain metastases in small-cell lung cancer: Pooled findings of NCT01780675 and PREMER trials
Lung CancerAbstractBackground: Cognitive decline is an arising concern in patients who need cranial irradiation. We used the pooled longitudinal individual patient data of two phase III trials: NCT01780675 and PREMER to...
-
Collij LE, Bollack A, La Joie R, Shekari M, Bullich S, Roé-Vellvé N, Koglin N, Jovalekic A, Garciá DV, Drzezga A, Garibotto V, Stephens AW, Battle M, Buckley C, Barkhof F, Farrar G, Gispert JD
Centiloid recommendations for clinical context-of-use from the AMYPAD consortium
Alzheimer's DementiaAbstractAmyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer's disease (AD)...
-
Collij LE, Bischof GN, Altomare D, Bader I, Battle M, Vállez García D, Lopes Alves I, Wolz R, Gismondi R, Stephens A, Walker Z, Scheltens P, Nordberg A, Gispert JD, Drzezga A, Perissinotti A, Morbelli S, Buckley C, Garibotto V, Frisoni GB, Farrar G, Barkhof F;
Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study
Journal of Nuclear MedicineAbstractSeveral studies have demonstrated strong agreement between routine clinical visual assessment and quantification, suggesting that quantification approaches could support assessment by less experienced...
-
Simrén J, Ashton NJ, Suárez-Calvet M, Zetterberg H
Alzheimer's disease-Biomarkers, clinical evaluation or both?
Journal of Neuropsychology -
Del Campo M, Quesada C, Vermunt L, Peeters CFW, Hok-A-Hin YS, Trieu C, Braber AD, Verberk IMW, Visser PJ, Tijms BM, van der Flier WM, Teunissen CE
CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals
Molecular NeurodegenerationAbstractThis preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune...
